D4-鸟苷酸解离抑制因子在肺癌发病机制中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.03.014

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (3): 206-208.doi: 10.3760/cma.j.issn.1673-422X.2014.03.014

D4-鸟苷酸解离抑制因子在肺癌发病机制中的研究进展

罗新岳, 胡瑞成, 戴爱国

410016 长沙，南华大学附属省马王堆医院

出版日期:2014-03-08 发布日期:2014-03-17
通讯作者: 胡瑞成，E-mail: huruicheng@hotmail.com E-mail:huruicheng@hotmail.com
基金资助:
国家自然科学基金(81070035)

Research progress of D4-GDI in the pathogenesis of lung cancer

LUO Xin-Yue, HU Rui-Cheng, DAI Ai-Guo

University of South China Affiliated Provincial Mawangdui Hospital, Changsha 410016, China

Online:2014-03-08 Published:2014-03-17
Contact: Hu Ruicheng, E-mail: huruicheng@hotmail.com E-mail:huruicheng@hotmail.com

摘要/Abstract

摘要： D4-鸟苷酸解离抑制因子（GDI）是Rho GDP解离抑制因子家族的主要成员之一，抑制Rho蛋白与GDP解离，参与细胞的收缩、黏附、迁移、增殖、凋亡等多种生物学行为。目前已证实D4-GDI参与了肺癌等多种呼吸系统疾病的病理生理过程，干预D4-GDI的表达能够改善这些疾病的病理改变与预后。

关键词: 细胞凋亡, 炎症, 信号通路, 肺肿瘤, D4-GDI

Abstract: As one of the main members of the Rho GDI dissociation inhibitory factors, D4-GDI inhibits the dissociation of Rho protein and GDP, which is also involved in a wide range of celluar functions, such as cell contraction, adhesion, migration, proliferation and apoptosis. Recently, accumulating evidence has been suggested that D4-GDI is involved in the pathogenesis of several pulmonary diseases, such as lung cancer. Intervention of D4-GDI expression may improve the pathological changes and prognosis of these diseases.

Key words: Apoptosis, Inflammation, Signaling pathway, Lung neoplasms, D4-GDI

罗新岳, 胡瑞成, 戴爱国. D4-鸟苷酸解离抑制因子在肺癌发病机制中的研究进展[J]. 国际肿瘤学杂志, 2014, 41(3): 206-208.

LUO Xin-Yue, HU Rui-Cheng, DAI Ai-Guo. Research progress of D4-GDI in the pathogenesis of lung cancer[J]. Journal of International Oncology, 2014, 41(3): 206-208.

参考文献

［1］ GarciaMata R, Boulter E, Burridge K. The ′invisible hand′: regulation of RHO GTPases by RHOGDIs［J］. Nat Rev Mol Cell Biol, 2011, 12(8):493504. ［2］ Boulter E, GarciaMata R, Guilluy C, et al. Regulation of Rho GTPase crosstalk,degradation and activity by RhoGDI1［J］. Nat Cell Biol, 2010, 12(5)：477483. ［3］ Zeller C, Dai W, Steele NL, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling［J］. Oncogene, 2012, 31(42):45674576. ［4］ Cho HJ, Baek KE, Park SM, et al. RhoGDI2 confers gastric cancer cells resistance against cisplatininduced apoptosis by upregulation of Bcl2 expression［J］. Cancer Lett, 2011, 311(1):4856. ［5］ Griner EM, Theodorescu D. The faces and friends of RhoGDI2［J］. Cancer Metastasis Rev, 2012, 31(34):519528. ［6］曹文枫，孙保存. Rho 蛋白与细胞骨架调节的细胞运动［J］. 中国肿瘤临床, 2009, 36(14):835837. ［7］ Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer［J］. Cancer Metastasis Rev, 2009, 28(34):327333. ［8］ Smith SC, Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins［J］. Nat Rev Cancer, 2009, 9(4):253264. ［9］ Steeg PS, Horak CE, Miller KD. Clinicaltranslational approaches to the Nm23H1 metastasis suppressor［J］. Clin Cancer Res, 2008, 14(16):50065012. ［10］ Kischel P, Waltregny D, Dumont B,et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting［J］. Int J Cancer, 2010, 126(3):640650. ［11］ Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation,cancer, and metastasis［J］. Cancer Metastasis Rev, 2010, 29(2):295307. ［12］ Kim S, Takahashi H, Lin WW, et al. Carcinomaproduced factors activate myeloid cells through TLR2 to stimulate metastasis ［J］. Nature, 2009, 457(7225):102106. ［13］ Asplund A, StillemarkBillton P, Larsson E, et al. Hypoxic regulation of secreted proteoglycans in macrophages［J］. Glycobiology, 2010, 20(1):3340. ［14］ Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breasttumour metastasis［J］. Nature, 2011, 475(7355):222225. ［15］ Said N, SanchezCarbayo M, Smith SC, et al. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration［J］. J Clin Invest, 2012, 122(4):15031518. ［16］ Gao D, Wan L, Inuzuka H, et al. Rictor forms a comlex with Cullin1 to promote SGK1 ubiquitination and destruction［J］. Mol Cell, 2010, 39(5):797808. ［17］ Agarwal NK, Chen CH, Cho H, et al. Rictor regulates cell migration by suppressing RhoGDI2［J］. Oncogene, 2013, 32(20):25212526. ［18］ McDonald PC, Oloumi A, Mills J, et al. Rictor and integrinlinked kinase interact and regulate Akt phosphorylation and cancer cell survival［J］. Cancer Res, 2008, 68(6):16181624.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	任露, 谢晓丽, 张坤, 王丽娟. 双氢青蒿素联合卡非佐米对多发性骨髓瘤细胞活性、增殖、凋亡的影响及机制研究[J]. 国际肿瘤学杂志, 2024, 51(3): 129-136.
[6]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[7]	张科平, 赵永生, 杨娟, 付茂勇. 绿原酸通过抑制PI3K-Akt信号通路诱导肺癌A549细胞线粒体功能障碍[J]. 国际肿瘤学杂志, 2024, 51(1): 21-28.
[8]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[9]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪. 脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[10]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[11]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇. Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[12]	何广思, 王军, 冯蒙蒙. 外周血细胞炎症标志物对晚期非小细胞肺癌免疫治疗预后的预测价值[J]. 国际肿瘤学杂志, 2023, 50(6): 321-327.
[13]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[14]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[15]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.

D4-鸟苷酸解离抑制因子在肺癌发病机制中的研究进展

Research progress of D4-GDI in the pathogenesis of lung cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价